AXENT BIOSCIENCES INC.

Biotech · Private

Proprietary 3D synthetic hydrogel culture system for manufacturing human embryonic stem cell-derived dopaminergic neurons for cell replacement therapy

Grants
$686K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Thermoreversible 3D Manufacturing Platform for Scalable Production of Dopaminergic Neurons for Parkinson's Disease Therapy$422,167
Federal grantDepartment of Health and Human Services · Phase I · A Thermoreversible 3D Manufacturing Platform for Scalable Production of Dopaminergic Neurons for Parkinson's Disease Therapy$263,672
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2406ONCOBLAZE LLC——
2407INNOVIMMUNE BIOTHERAPEUTICS HOLDING, LLC——
2408FLIK THERAPEUTICS, INC.——
2409AXENT BIOSCIENCES INC.——
2410CELLGRO TECHNOLOGIES, LLC——
2411GLAX, LLC——
2412AMPEDRNA BIOSCIENCES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 7
  • Methods For Production Of Functional Neuronsapplication
  • Thermoreversible Polymers With Improved Stability And Methods And Uses Thereofapplication
  • Thermoreversible Polymers With Improved Stability And Methods And Uses Thereofapplication
  • Methods For Production Of Functional Neuronsapplication
  • Methods For Production Of Functional Neuronsapplication
  • Thermoreversible Polymers With Improved Stability And Methods And Uses Thereofapplication
  • Efficient Generation Of Gabaergic Cortical Interneurons From Human Pluripotent Stem Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.